ATE536353T1 - 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren - Google Patents

2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren

Info

Publication number: ATE536353T1
Authority: AT; Austria
Prior art keywords: oxadiazole; amino; protein kinase; kinase inhibitors; imidazole compounds
Prior art date: 2003-08-20

Application number

AT04781796T

Other languages

English (en)

Inventor

Jon Come

Jeremy Green

Craig Marhefka

Scott Harbeson

Ly Pham

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-20

Filing date

2004-08-20

Publication date

2011-12-15

2004-08-20 Application filed by Vertex Pharma filed Critical Vertex Pharma

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE536353T1 publication Critical patent/ATE536353T1/de

Links

DMWHFBGPDVBKLA-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)-2h-1,2,5-oxadiazol-3-amine Chemical class N=1C=CNC=1C1(N)NON=C1 DMWHFBGPDVBKLA-UHFFFAOYSA-N 0.000 title 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
102000001253 Protein Kinase Human genes 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)

AT04781796T 2003-08-20 2004-08-20 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren ATE536353T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49661703P	2003-08-20	2003-08-20
PCT/US2004/027182 WO2005019190A2 (en)	2003-08-20	2004-08-20	(4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE536353T1 true ATE536353T1 (de)	2011-12-15

Family

ID=34216023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04781796T ATE536353T1 (de)	2003-08-20	2004-08-20	2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren

Country Status (7)

Country	Link
US (1)	US7157476B2 (de)
EP (1)	EP1660467B1 (de)
JP (1)	JP2007512230A (de)
AT (1)	ATE536353T1 (de)
AU (1)	AU2004267094A1 (de)
CA (1)	CA2536253A1 (de)
WO (1)	WO2005019190A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1694686A1 (de)	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinaseinhibitoren
WO2005087747A1 (en) *	2004-03-08	2005-09-22	Wyeth	Ion channel modulators
US20070191448A1 (en) *	2004-03-08	2007-08-16	Robert Zelle	Ion channel modulators
CA2575466A1 (en) *	2004-08-13	2006-02-23	Genentech, Inc.	Thiazole based inhibitors of atp-utilizing enzymes
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
EP1812439B2 (de)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinaseinhibitoren
EP1809282B1 (de)	2004-10-18	2013-01-09	Amgen, Inc	Thiadiazol-verbindungen und anwendungsverfahren
JPWO2006104280A1 (ja) *	2005-03-31	2008-09-11	武田薬品工業株式会社	糖尿病の予防・治療剤
PL1879573T3 (pl)	2005-05-10	2013-05-31	Incyte Holdings Corp	Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US8450351B2 (en)	2005-12-20	2013-05-28	Incyte Corporation	N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007084391A2 (en) *	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors
JP5258563B2 (ja) *	2006-06-29	2013-08-07	日産化学工業株式会社	αアミノ酸誘導体及びそれを有効成分として含む医薬
KR100783585B1 (ko)	2006-08-22	2007-12-07	한국생명공학연구원	스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
WO2008036642A2 (en)	2006-09-19	2008-03-27	Incyte Corporation	N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es)	2006-09-19	2008-02-08	Incyte Corp	Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP2079739A2 (de) *	2006-10-04	2009-07-22	Pfizer Products Inc.	Pyrido[4,3-d]pyrimidin-4(3h)-onderivate als kalziumrezeptorantagonisten
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
EP2223925A1 (de) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase-Inhibitoren
CN101573352A (zh)	2006-10-21	2009-11-04	艾博特股份有限两合公司	杂环化合物和其作为糖原合酶激酶3抑制剂的用途
US20100022517A1 (en) *	2006-12-18	2010-01-28	Richards Lori A	Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en)	2006-12-18	2011-12-06	Inspire Pharmaceuticals, Inc.	Cytoskeletal active rho kinase inhibitor compounds, composition and use
US7919504B2 (en) *	2007-07-17	2011-04-05	Amgen Inc.	Thiadiazole modulators of PKB
EP2173728A2 (de) *	2007-07-17	2010-04-14	Amgen Inc.	Heterocyclische pkb-modulatoren
US8158656B2 (en) *	2008-05-16	2012-04-17	Shenzhen Chipscreen Biosciences Ltd.	2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
US20090325959A1 (en) *	2008-06-26	2009-12-31	Vittitow Jason L	Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US8410147B2 (en) *	2008-06-26	2013-04-02	Inspire Pharmaceuticals, Inc.	Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8207195B2 (en) *	2008-06-26	2012-06-26	Inspire Pharmaceuticals, Inc.	Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) *	2008-06-26	2009-12-31	Fulcher Emilee H	Method for treating inflammatory diseases using rho kinase inhibitor compounds
US20100008968A1 (en) *	2008-06-26	2010-01-14	Lampe John W	Method for treating cardiovascular diseases using rho kinase inhibitor compounds
JP5465720B2 (ja)	2008-07-08	2014-04-09	インサイト・コーポレイション	インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
GB0812648D0 (en) *	2008-07-10	2008-08-20	Prosidion Ltd	Compounds
US20100204210A1 (en) *	2008-12-04	2010-08-12	Scott Sorensen	Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8211901B2 (en)	2009-05-22	2012-07-03	Shenzhen Chipscreen Biosciences Ltd.	Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh)	2009-06-04	2013-03-13	深圳微芯生物科技有限责任公司	作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US10463838B2 (en)	2009-08-19	2019-11-05	Medline Industries, Inc	Vascular access methods and devices
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en)	2010-04-23	2015-09-15	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2955176B1 (de) *	2010-06-15	2017-12-06	Bayer Intellectual Property GmbH	Zusammensetzung enthaltend kristalline modifikation b von (3-chloropyridin-2-yl)-n-[4-cyano-2-methyl-6-(methylcarbamoyl)phenyl]-3-([5-(trifluormethyl)-2h- tetrazol-2-yl]methyl)-1h-pyrazol-5-carboxamid und ihre verwendung
MX336726B (es)	2010-09-27	2016-01-27	Abbott Gmbh & Co Kg	Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8759380B2 (en)	2011-04-22	2014-06-24	Cytokinetics, Inc.	Certain heterocycles, compositions thereof, and methods for their use
US20150258127A1 (en)	2012-10-31	2015-09-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
ES2799582T3 (es)	2013-11-08	2020-12-18	Incyte Holdings Corp	Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
US11478457B2 (en) *	2015-04-23	2022-10-25	Nutech Ventures	Castration-resistant prostate cancer
WO2020201073A1 (en)	2019-03-29	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
WO2021233882A1 (en) *	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN115916789B (zh) *	2020-05-22	2025-06-27	勃林格殷格翰国际有限公司	制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
US20240300939A1 (en)	2021-06-14	2024-09-12	Scorpion Therapeutics, Inc.	Urea derivatives which can be used to treat cancer
EP4643858A1 (de)	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Verfahren und pharmazeutische zusammensetzung zur behandlung von gebärmuttererkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
WO2002032896A1 (en) *	2000-10-16	2002-04-25	Novo Nordisk A/S	Furazanyl-triazole derivates for the treatment of diseases
WO2003066629A2 (en)	2002-02-06	2003-08-14	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds useful as inhibitors of gsk-3
AR043057A1 (es)	2002-10-30	2005-07-13	Vertex Pharma	Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa

2004
- 2004-08-20 CA CA002536253A patent/CA2536253A1/en not_active Abandoned
- 2004-08-20 AU AU2004267094A patent/AU2004267094A1/en not_active Abandoned
- 2004-08-20 AT AT04781796T patent/ATE536353T1/de active
- 2004-08-20 US US10/922,575 patent/US7157476B2/en not_active Expired - Lifetime
- 2004-08-20 EP EP04781796A patent/EP1660467B1/de not_active Expired - Lifetime
- 2004-08-20 WO PCT/US2004/027182 patent/WO2005019190A2/en not_active Ceased
- 2004-08-20 JP JP2006524089A patent/JP2007512230A/ja active Pending

Also Published As

Publication number	Publication date
US20050148640A1 (en)	2005-07-07
AU2004267094A1 (en)	2005-03-03
US7157476B2 (en)	2007-01-02
WO2005019190A2 (en)	2005-03-03
EP1660467B1 (de)	2011-12-07
WO2005019190A3 (en)	2007-09-20
CA2536253A1 (en)	2005-03-03
EP1660467A2 (de)	2006-05-31
JP2007512230A (ja)	2007-05-17

Publication	Publication Date	Title
ATE536353T1 (de)	2011-12-15	2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
DE60332433D1 (de)	2010-06-17	Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de)	2010-07-01	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2007-07-15	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE450530T1 (de)	2009-12-15	Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE433973T1 (de)	2009-07-15	Azolylaminoazine als inhibitoren von proteinkinasen
DE602004024572D1 (de)	2010-01-21	Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004014117D1 (de)	2008-07-10	Thiazole zur verwendung als inhibitoren von protein-kinasen
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
DE602006004844D1 (de)	2009-03-05	Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE482213T1 (de)	2010-10-15	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE60214703D1 (de)	2006-10-26	Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
WO2005028475A3 (en)	2005-06-09	Compositions useful as inhibitors of protein kinases
ATE548363T1 (de)	2012-03-15	3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
DE60333387D1 (de)	2010-08-26	Triazolopyridazine als proteinkinase-inhibitoren
ATE464303T1 (de)	2010-04-15	Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20072567L (no)	2007-07-17	Triazoler nyttige som proteinkinase-inhibitorer
ATE425160T1 (de)	2009-03-15	Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
TW200607803A (en)	2006-03-01	Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
DE602004012578D1 (de)	2008-04-30	Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
DE602006017574D1 (de)	2010-11-25	Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE435858T1 (de)	2009-07-15	Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen